Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC Alvespimycin trifluoroacetate | 00-00-0 | MFCD08457919 | 99.0% | 730.77 g·mol⁻¹ | C34H49F3N4O10 | 25 MG
Alvespimycin trifluoroacetate (17-DMAG TFA) is the trifluoroacetic acid salt of a semisynthetic geldanamycin derivative that potently inhibits Hsp90. It binds Hsp90 in the low-nanomolar range and is used in cellular and biochemical studies to induce heat-shock response and promote degradation of Hsp90 client proteins, supporting research into proteostasis and targeted oncology pathways.
- Potent Hsp90 inhibition with reported EC50 ≈ 62 nM.
- Promotes Her2 degradation in cancer cell lines (EC50 8 nM in SKBR3, 46 nM in SKOV3).
- Induces Hsp70 expression in cell assays (EC50 4 nM in SKBR3, 14 nM in SKOV3).
- High purity (>98.9%) suitable for in vitro studies.
- Available in small research pack sizes, including 25 MG.
Medchemexpress LLC 7-TFA-ap-7-Deaza-dA | 178420-75-2 | 98.8% | 399.32 | 1 ML
7-TFA-ap-7-Deaza-dA is a modified nucleoside that can be used in the synthesis of deoxyribonucleic acid or nucleic acid. It functions as a click chemistry reagent, containing an alkyne group that undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules.
- Modified nucleoside.
- Can be used in the synthesis of deoxyribonucleic acid or nucleic acid.
- Functions as a click chemistry reagent.
- Contains an alkyne group for reactions.
- Undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide groups.
Medchemexpress LLC AS-99 TFA | 99.1% | C29H31F6N5O5S2 | 1 MG
AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50 of 0.79 μM, Kd of 0.89 μM) with anti-leukemic activity. It functions by blocking cell proliferation, inducing apoptosis and differentiation, downregulating MLL fusion target genes, and reducing the leukemia burden in vivo.
- Potent and selective ASH1L histone methyltransferase inhibitor
- Demonstrates anti-leukemic activity
- Blocks cell proliferation
- Induces apoptosis and differentiation
- Downregulates MLL fusion target genes
- Reduces leukemia burden in vivo
- Exhibits over 100-fold selectivity towards ASH1L over 20 other histone methyltransferases
- Suppresses MLL fusion driven transcriptional programs
- Leads to dose-dependent downregulation of canonical MLL fusion target genes
Medchemexpress LLC Tfllr-nh2(tfa) | 1313730-19-6 | 99.6% | 761.83 | 5 MG
TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM, intended for research use only. It appears as a white to off-white solid.
- Acts as a selective PAR1 agonist
- Stimulates concentration-dependent increases in [Ca2+]i in neurons
- Activated platelets upregulate E-cadherin and downregulate vimentin expression in SW620 cells
- Increases secreted TGF-β1 in platelet cultures
- Injection into rat paws stimulates marked and sustained oedema
- Stimulates Evans blue extravasation in various organs in wild-type mice
- Can induce both contraction and relaxation in rat duodenal smooth muscle
- Recommended storage for powder is -80°C for 2 years or -20°C for 1 year
- Recommended storage in solvent is -80°C for 6 months or -20°C for 1 month
- High solubility in DMSO and H2O (100 mg/mL)
Medchemexpress LLC PF15 (TFA) | 99.7% | C46H50F3N13O8 | 25 MG
PF15 TFA is a PROTAC that connects ligands for FLT3 kinase and CRBN. It is a highly selective FLT3-ITD degrader with a DC50 of 76.7 nM. It significantly inhibits the proliferation of FLT3-ITD-positive cells and can down-regulate the phosphorylation of FLT3 and STAT5. It also inhibits tumor growth in mouse models and can be used in the study of leukemia.
- Connects ligands for FLT3 kinase and CRBN
- Highly selective FLT3-ITD degrader
- Has a DC50 of 76.7 nM
- Inhibits proliferation of FLT3-ITD-positive cells
- Down-regulates the phosphorylation of FLT3 and STAT5
- Inhibits tumor growth in mouse models
- Used in the study of leukemia
Sigma Aldrich Fine Chemicals Biosciences Trifluoroacetic acid | 76-05-1 | MFCD00004169 | 4 x 2 mL
Trifluoroacetic acid | Purity: 99% | Mol Wt: 114.02 | 76-05-1 | MFCD00004169 | 4 x 2 mL
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 | 5 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. It significantly enhances the activation and proliferation of T cells, inhibits migration and metastasis, and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. It can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Reduces the viability of specific cell lines
- Decreases the proportion of cells in the S phase
- Induces apoptosis in certain cell types
- Inhibits cell migration in multiple cell lines
- Reduces MCAM and N-cadherin expression
- Reduces the number and size of liver metastases in animal models
- Shows a trend toward reducing tumor volume in primary tumor sites in animal models
Medchemexpress LLC M65 TFA | 99.98% | 4823.53 (free base) | 5 MG
M65 TFA is a deleted peptide of maxadilan (61 a.a.), specifically missing residues between positions 24 and 42. It functions as a specific antagonist of the PACAP type 1 receptor, inhibiting ANP secretion, and is utilized in relevant research.
- Deleted peptide of maxadilan (61 a.a.) with a deletion of residues between positions 24 and 42.
- Acts as a specific antagonist of the PACAP type 1 receptor.
- Inhibits ANP secretion.
- Completely blocks cAMP accumulation stimulated by 100 nM of VIP in rat cortical neurons at 1 μM concentration.
- Partially inhibits cAMP accumulation stimulated by 1 nM of maxadilan in rat cortical neurons at 1 μM concentration.
Medchemexpress LLC Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) | 96.6% | 7588.60 (free base) | 1 MG
Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) is a single-chain β-scorpion neurotoxic peptide and the main toxin found in scorpion venom. This peptide specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6, making it a valuable tool for research in ion channel modulation and neurological diseases.
- Neurotoxic peptide
- Specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6
- Functions as an ion channel modulator
- Useful in neurological disease research
- Acts as an inhibitor
Medchemexpress LLC JPS014 TFA | 98.12% | C48H60F3N7O9S | 25 MG
JPS014 TFA is a benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC). It degrades class I histone deacetylase (HDAC) and is a potent HDAC1/2 degrader. This degradation correlates with a greater number of total differentially expressed genes and enhanced apoptosis in HCT116 cells.
- Benzamide-based Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC)
- Degrades class I histone deacetylase (HDAC)
- Potent HDAC1/2 degrader
- Correlates with greater total differentially expressed genes
- Enhances apoptosis in HCT116 cells
Medchemexpress LLC Fn-439 TFA | 124168-73-6 | MFCD00237459 | 99.8% | 604.58 g·mol⁻¹ | C25H35F3N6O8 | 5 MG
FN-439 TFA is the trifluoroacetic acid salt of FN-439, a selective small-molecule inhibitor of collagenase-1 (matrix metalloproteinase). It inhibits collagenase-1 with an IC50 of 1 μM and is supplied as a research reagent for in vitro studies of cancer and inflammatory processes.
- Selective collagenase-1 inhibitor with reported IC50 of 1 μM.
- High purity (99.81%) suitable for biochemical assays.
- Trifluoroacetic acid salt form to aid solubility in aqueous systems.
- Supplied in research-scale quantities (e.g., five mg) for assay development.
- Intended for in vitro research applications; not for human use.
Medchemexpress LLC Wd6305 Tfa | 99.8% | 1226.40 | 5 MG
WD6305 TFA is a potent and selective PROTAC degrader targeting METTL3-METTL14. It inhibits m6A modification and proliferation of AML cells, and induces apoptosis. This compound also exhibits antitumor activity.
- Potent and selective PROTAC degrader
- Targets METTL3 and METTL14
- Inhibits m6A modification
- Inhibits proliferation of AML cells
- Induces apoptosis
- Exhibits antitumor activity